SN-38

Catalog No.S4908

SN-38 Chemical Structure

Molecular Weight(MW): 392.4

SN-38 is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks.

Size Price Stock Quantity  
USD 90 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • (B) HCT116 cells were treated with increasing doses of SN-38 and treated with 4 nM SN-38 for different time. Cell extracts were prepared and analyzed by Western blotting with indicated antibody. These experiments were repeated thrice. (C) HCT116 cells were transfected with 2 μg of EGFP-LC3 construct. At 8 h post-transfection, cells were treated with 4 nM of SN-38 for 48 h. And then cells were examined by confocal microscopy (magnification × 400). The percentage of cells showing accumulation of EGFP-LC3 in puncta (EGFP-LC3vac) was quantified. (D) LOVO and HCT116 cells were treated with 2 nM and 4 nM of SN-38 combined with 10 mM of 3-Methyladenine (3-MA) for 48 h respectively. Cell extracts were prepared and analyzed by Western blotting with indicated antibody. These experiments were repeated thrice. (E) Cells were treated with indicated concentrations of 3-MA and SN-38 for 48 h. Cell apoptosis was assessed by Annexin V-FITC/PI staining assay by flow cytometry. Columns, means of three determinations; bars, SD. (F) and (G) LOVO and HCT116 cells were transfected with 50 nM of NC siRNA, ATG5 siRNA respectively, and then were treated with increasing doses of SN-38 for 48 h, the knockdown effects on ATG5 were confirmed by Western blot analysis (upper panel). Cell viability was measured using CCK8 assay. Columns, means of three determinations; bars, SD.

    Free Radic Biol Med, 2017, 104:280-297. SN-38 purchased from Selleck.

    HCT116 cells were pretreated with tested compounds for 1 hour and then cotreated with 1 μM SN-38 for 2 hours. Cell lysates were then subjected to Western blot analysis. Data shown are representative of three independent experiments. Con, concentration.

    J Pharmacol Exp Ther 2014 348(3), 432-41. SN-38 purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description SN-38 is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks.
Targets
Topo I [1]
(Cell-free assay)
In vitro

SN-38, a biological active metabolite of irinotecan hydrochloride (CPT-11). SN-38 causes the strongest inhibition of DNA topoisomerase I, followed by CPT and then CPT-11. CPT-11 dose dependently shifts the position of relaxed DNA in the direction of nicked DNA, but SN-38 and CPT shows no effect on the position of relaxed DNA. SN-38 dose-dependently and time-dependently inhibit DNA synthesis. Respective IC50 values of SN-38, in DNA synthesis is 0.077 μM. The inhibitory effect of SN-38 on RNA synthesis is less than that on DNA synthesis and it does not inhibit protein synthesis. SN-38 caused frequent DNA single-strand breaks in P388 cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human PC6 cells NH\pSIlRem:uaX\ldoF1cW:wIHHzd4F6 MnTEOkBl[Xm| MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFNjDj[YxteyClYYLyfYlv\yCyUlOgZYZ1\XJiNjDkZZl{NCCLQ{WwQVAvPDNibl2= MXixPVI2PDh2Mx?=
human HCT116 cells NUC1WHgzWHKxbHnm[ZJifGmxbjDhd5NigQ>? MWWzJIRigXN? MnnGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiMzDkZZl{NCCLQ{WwQVAvPTVibl2= M2[2SFE6OjV2OESz
human PC3 cells Mmq4R5l1d3SxeHnjxsBie3OjeR?= NXSwXI9WPzJiaB?= MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOg[ZhxemW|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9Nk43KG6P NX;QWpVxOjJ7NUmyOFY>
human A549 cells NUmydJltS3m2b4TvfIlkyqCjc4PhfS=> M4Du[lMh\GG7cx?= M{nNbWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhOyCmYYnzJIJ6KFOUQjDhd5NigSxiSVO1NF0zNjd{IH7N MoHSNlQ2Ojl6N{C=
human QG56 cells MUHQdo9tcW[ncnH0bY9vKGG|c3H5 NGPOSIg{KGSjeYO= MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFGJNU[gZ4VtdHNiYX\0[ZIhOyCmYYnzMEBKSzVyPUKuPEBvVQ>? NULPUVgxOTl{NUS4OFM>
human NCI-H460 cells Ml32VJJwdGmoZYLheIlwdiCjc4PhfS=> MkPZN{Bl[Xm| NX\OR4MzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA{KGSjeYOsJGlEPTB;Mz6zJI5O MV6xPVI2PDh2Mx?=
human DU145 cells M3nweHBzd2yrZnXyZZRqd25iYYPzZZk> NX7ke5hxQTZiaB?= MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHHmeIVzKDl4IHjyd{whUUN3ME20JI5O M{TUcFE5Ojd4MUSx
human breast cancer cell line (SK-BR-3) MYPDfZRwfG:6aXRCpIF{e2G7 NYq5folnUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxtKGyrbnWgLHNMNUKULUOpMEBKSzVyPUSgcm0> M3fJc|EyOzN2NU[5
human KB3-1 cells NUHYUFN7S3m2b4TvfIlkyqCjc4PhfS=> NUn2dYNkPCCmYYnz M3jKe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDOy1zIHPlcIx{KGGodHXyJFQh\GG7czDifUBOXFRibXX0bI9lNCCLQ{WwQVQhdk1? Mkj0NVk{ODN|ME[=
human HCT116 cells NFXHNJREgXSxdH;4bYPDqGG|c3H5 MUW3NkBp MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:PC5{ODDuUS=> NX3GR3J3OjV6M{WzOVk>
MDA-MB-435 S human breast cancer cells MVrGeY5kfGmxbjDhd5NigQ>? M2DUOGlvcGmkaYTpc44h[WejaX7zeEBOTEFvTVKtOFM2KFNiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCrbjD0bIUh[WK|ZX7j[UBw\iCjbHL1cYlvNCCLQ{WwQVUhdk1? NYH4V4ZrOTFyNUK4NFI>
human HT-29 cells NF7xb45EgXSxdH;4bYPDqGG|c3H5 MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{whUUN3ME21Mlkhdk1? NGTvWoIzOTR5MEi2OC=>
human lung cancer cell line (H128) MY\DfZRwfG:6aXRCpIF{e2G7 Mkm3TY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcJVv\yClYX7j[ZIh[2WubDDsbY5mKCiKMUK4LUwhUUN3ME22JI5O NWfERVdVOTF|M{S1Olk>
human MIA PaCa cells NGX5cWxRem:uaX\ldoF1cW:wIHHzd4F6 NXHyPHJXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNTWEhWGGFYTDj[YxteyCjZoTldkA6PiCqcoOsJGlEPTB;NjDuUS=> NVjRXW9OOTh{N{[xOFE>
human HCT116 colon cancer cell line MVTGeY5kfGmxbjDhd5NigQ>? NGHyRnZKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDoeY1idiCKQ2SxNVYh[2:ub36gZ4Fv[2W{IHPlcIwhdGmwZTygTWM2OD15IH7N MYexOVgxQDR3Nh?=
human stomach cancer cell line (MKN45) NGfnUVJEgXSxdH;4bYPDqGG|c3H5 NEjWSFRKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB{fG:vYXPoJINidmOncjDj[YxtKGyrbnWgLG1MVjR3KTygTWM2OD16IH7N Ml3vNVE{OzR3Nkm=
human A2780 cells MYjDfZRwfG:6aXRCpIF{e2G7 MVu3NkBp M3v3XWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJIFteGijNXLleIE{KGmwdHXndolvKGG|c3Xzd4VlKGG|IHPlcIwhe3W{dnn2ZYwh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME25JI5O NXjvOHBWOjJ7NUmyOFY>
human ovarian cancer cell line (SK-OV-3) MV3DfZRwfG:6aXRCpIF{e2G7 NWmwOWsxUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hd3[jcnnhckBk[W6lZYKgZ4VtdCCuaX7lJEhUUy2RVj2zLUwhUUN3ME2xNUBvVQ>? MYGxNVM{PDV4OR?=
human DU145 prostate cell line NFKyRZNRem:uaX\ldoF1cW:wIHHzd4F6 MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JJBzd3O2YYTlJINmdGxibHnu[UwhUUN3ME2xN{BvVQ>? MluyNVA1QTh{MU[=
human colon cancer cell line (WiDr) M4LpRWN6fG:2b4jpZ:Kh[XO|YYm= MlnXTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9NVQhdk1? NH7odnoyOTN|NEW2PS=>
human lung cancer cell line (A549) NIO2epREgXSxdH;4bYPDqGG|c3H5 M1;sZWlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHygcIlv\SBqQUW0PUk> MX6xNVM{PDV4OR?=
human tumor HL60 cell-line NX;WNVVvTnWwY4Tpc44h[XO|YYm= M4rJNVMh\GG7cx?= MoSzTY4ufmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIH\vdkBpfW2jbjD0eY1weiCKTE[wJINmdGxvbHnu[UB4[XNiZHX0[ZJucW6nZDD1d4lv\yCVUlKgZZN{[XliYX\0[ZIhOyCmYYnzJI9nKGmwY4XiZZRqd25uIFnDOVA:OTlibl2= NGrUcJYyPTlzM{m5Oi=>
PC-3 carcinoma cell line MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVLBOI5[S2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JIdzd3e2aDDv[kBpfW2jbjDwdo9{fGG2ZTDQR{0{KGOjcnPpco9u[SClZXzsJIxqdmVuIFnDOVA:OzVwNjDuUS=> MXuxOVQ2PDJ|MB?=
human KBV1 cells MWfDfZRwfG:6aXRCpIF{e2G7 MnfSOEBl[Xm| MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBOTFJzIH;2[ZJmgHC{ZYPzbY5oKGi3bXHuJGtDXjFiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JG1VXCCvZYToc4QtKEmFNUC9OFYhdk1? NYGyR2ZvOTl|MEOzNFY>
human A549 cells MmXMR5l1d3SxeHnjxsBie3OjeR?= NVztSXltS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyxiSVO1NF01PyCwTR?= NGLhXHAzOTR5MEi2OC=>
NSCLC-H460 M{nhe2N6fG:2b4jpZ:Kh[XO|YYm= NG\me5VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBvd25vc33hcIwu[2WubDDseY5oKGOjcnPpco9u[SClZXzsJIxqdmViSES2NEApVlOFTFOtTFQ3OCluIFnDOVA:QDBibl2= M2PqcFEyPTZ|OUK1
MDA-MB-435 S human breast cancer cells NEPsfFNHfW6ldHnvckBie3OjeR?= MonpTY5pcWKrdHnvckBi\2GrboP0JG1FSS2PQj20N|UhWyCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGmwIITo[UBxemW|ZX7j[UBw\iB|MDDt[{9uVCCKU1GsJGlEPTB;NUCgcm0> MoDaNVExPTJ6MEK=
human H460 cell NInDR3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2PRV2lvcGmkaYTpc44hd2ZiaIXtZY4hUDR4MDDj[YxtKGe{b4f0bEwhUUN3ME24NEBvVQ>? M{PtNVE3QTF|N{C2
human MDA-MB-231 cells NE\0O2tEgXSxdH;4bYPDqGG|c3H5 M2KxbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOsJGlEPTB;MUe2JI5O MoOwNlQ2Ojl6N{C=
human KBH5.0 cells MYXDfZRwfG:6aXRCpIF{e2G7 M2nQW|Qh\GG7cx?= M1:xemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKFUmCgc5ZmemW6cILld5NqdmdiaIXtZY4hU0KKNT6wJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCPVGSgcYV1cG:mLDDJR|UxRTBwMzFOwG0> M3jldFE6OzB|M{C2
human MCF-7 breast cell line Mk\XVJJwdGmoZYLheIlwdiCjc4PhfS=> MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRj23JIJz\WG|dDDj[YxtKGyrbnWsJGlEPTB;MD6zO{DPxE1? NEPTXoUyODR7OEKxOi=>
human SKOV-3 ovarian cell line M1viNHBzd2yrZnXyZZRqd25iYYPzZZk> NFjTNG1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLU3YuOyCxdnHybYFvKGOnbHygcIlv\SxiSVO1NF0xNjd{IN88US=> NVTMR2lmOTB2OUiyNVY>
human Bel-7402 liver cancer cell line MVnGeY5kfGmxbjDhd5NigQ>? MorjTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4hSmWuLUe0NFIhdGm4ZYKgZ4Fv[2W{IHPlcIwhdGmwZTygTWM2OD1|LkG5JO69VQ>? M2DSUlE2QDB6NEW2
HEK293 cells MkPQR5l1d3SxeHnjxsBie3OjeR?= MkfTO|IhcA>? MX3JcpRzcW6|aXOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5 MnPHNlUzPzJyNUW=

... Click to View More Cell Line Experimental Data

In vivo After oral dosing, peak SN-38 concentrations occurrs within 1 h, and the The percent unbound SN-38 lactone in murine plasma at 1000 ng/mL is 3.4 +/- 0.67%, whereas at 100 ng/mL the percent unbound is 1.18 +/- 0.14%. SN-38 lactone AUCs in micebearing human neuroblastoma xenografts are greater than in nontumor-bearing animals. [2]

Protocol

Kinase Assay:[1]
+ Expand

Topoisomerase I Assay:

One unit (the minimum amount for full relaxation of 0.5 μg SV40 DNA under the conditions of this study) of topoisomerase I, 0.5 μL of the test compounds, and 0.5μg SV40 DNA are added sequentially to the reaction buffer, which is composed of 25 mM Tris-HCl (pH 7.5), 50 mM KC1, 5 mM MgCl2, 0.25 mM EDTA disodium salt, 0.25 mM dithiothreitol, 15μg /mL bovine serum albumin, and 5% glycerol. Then, the reaction mixture (50 μL) is incubated for 10 min at 37 °C, and the reaction is terminated by treatment with 7.5 μL of a solution consisting of 1% sodium dodecyl sulfate, 20 mM EDTA disodium salt, and 0.5 mg/mL proteinase K for an additional 30 min at 37°C. The samples are mixed with 5 μL of the loading buffer containing 10 mM Na2HPO4, 31.3% sucrose, and 0.3% bromophenol blue. Relaxed (form Ir) DNA is separated from supercoiled (form I) and nicked (form II) DNA by electrophoresis on 0.8% agarose gel at 50 mA and 20 V for 17 h in the presence of 2 μg/mL chloroquine, 10 mM EDTA, 30 mM NaH2PO4, and 36 Mm Tris-HCl (pH 7.8). After electrophoresis, the gel is stained with 0.05% ethidium bromide and photographed with UV light (302 nm). The amount of DNA is quantified using a densitometer.
Cell Research:[3]
+ Expand
  • Cell lines: A-172, U-87, and LA-567
  • Concentrations: 0 -1000 nM
  • Incubation Time: 48 h
  • Method: MTT assay
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 21 mg/mL (53.51 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 392.4
Formula

C22H20N2O5

CAS No. 86639-52-3
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00311610 Completed Colorectal Cancer Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) January 2006 Phase 2
NCT00046540 Completed Neoplasms INSYS Therapeutics Inc October 2002 Phase 1
NCT00104754 Withdrawn Lung Cancer Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) null Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy SN-38 | SN-38 supplier | purchase SN-38 | SN-38 cost | SN-38 manufacturer | order SN-38 | SN-38 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID